BCL2 and acute myeloid leukemia: Knockout of TP53 resulted in decreased MCL-1 and BCL-2 levels, ultimately decreasing sensitivity to venetoclax [110], suggesting that TP53-mutated AML cells are more dependent on MCL-1 than BCL-2 for survival.